Phase 3Data readout

VK2735 (Injectable)

Metabolic disorder, Obesity

VKTXViking Therapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: VK2735 (Injectable)
Development stage: Phase 3
Event type: Data readout
Indication: Metabolic disorder, Obesity

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for VK2735 (Injectable) in Metabolic disorder, Obesity. The expected timing is based on the latest available company guidance and may change.

Development notes

07/29/26:- VANQUISH trials advancing. Phase 3 readout expected in 2027. Maintenance data expected Q3 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source